Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Exelixis, Inc. is a biotechnology company dedicated to the discovery and development of novel therapeutics that will potentially enhance the care and lives of patients with cancer and other serious diseases. The company is leveraging its fully integrated gene-to-drug platform to fuel the growth of its proprietary drug pipeline. Exelixis’ development pipeline covers cancer and metabolism and is comprised of the following compounds: XL119 (becatecarin), for which a multinational Phase III clinical trial in bile duct tumors is ongoing and which has been exclusively licensed to Helsinn Healthcare ( www.exelixis.com )
Exelixis , Inc.
170 Harbor Way P O Box 511
South San Francisco, California 94083
USA
Tel: (650) 825-2200
Fax: (650) 837-8300